The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy

Figure 1

(a–d) Case (1) IDC, grade 3 (lymphocyte predominant); 10% ITL, 70% SL (H&E 40×), (b) Ki67 IHC (40×) proliferation index 40%, (c) CD3 IHC (40×), 60%, (d) CD20 IHC (40×), 40%. (e–h) Case [2] IDC, grade 3 (intermediate group); 20% ITL, 40% SL (H&E) (10×), (f) Ki67 IHC (10×) proliferation index 60%, (g) CD3 IHC (40×), 60%, (h) CD20 IHC (40×), 20%. (i–l) Case [3] IDC, grade 2 (lymphocyte poor); 5% ITL, 10% SL (H&E (40×), (j) Ki67 IHC (40×) proliferation index 5%, (k) CD3 IHC (40×), 70%, (l) CD20 IHC (40×), 10%. (m–p) Case [4] Medullary carcinoma, grade 3 (lymphocyte predominant); 30% I1L, 80% SL (H&E (40×), (n) Ki67 IHC (40×) proliferation index 90%, (o) CD3 IHC (40×), 60%, (p) CD20 IHC (40×), 30%. (q–t) Case [5] ILC, grade 2 (intermediate group); 5% ITL, 40% SL (H&E 10×), (r) Ki67 IHC (40×) proliferation index 50%, (s) CD3 IHC (40×), 50%, (t) CD20 IHC (40×), 5%.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)

(q)

(r)

(s)

(t)